Bright Minds Biosciences Inc. (DRUG)
| Market Cap | 183.29M -54.5% |
| Revenue (ttm) | n/a |
| Net Income | -17.26M |
| EPS | -2.03 |
| Shares Out | 9.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 197,379 |
| Open | 21.29 |
| Previous Close | 20.70 |
| Day's Range | 20.70 - 23.39 |
| 52-Week Range | 17.40 - 123.75 |
| Beta | 0.23 |
| Analysts | Strong Buy |
| Price Target | 122.44 (+432.35%) |
| Earnings Date | Aug 17, 2026 |
About DRUG
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neurop... [Read more]
Analyst Summary
According to 9 analysts, the average rating for DRUG stock is "Strong Buy." The 12-month stock price target is $122.44, which is an increase of 432.35% from the latest price.
News
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Bright Minds Biosciences (DRUG)
Bright Minds Biosciences shares sold off after the FDA placed the Company's planned Phase 2 BMB-101 epilepsy trial on partial clinical hold, citing mouse toxicity findings. Levi & Korsinsky is investi...
BRIGHT MINDS BIOSCIENCES INVESTIGATION: DRUG Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Bright Minds Biosciences (“Bright Minds” or the “Company”) (NASDAQ: DRUG). The...
DRUG SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Bright Minds Biosciences
Investors who lost money when DRUG shares sold off on the FDA's partial clinical hold for the planned Phase 2 BMB-101 epilepsy trial may have the right to seek recovery, even if they have already sold...
Bright Minds price target lowered to $107 from $126 at Baird
Baird lowered the firm’s price target on Bright Minds (DRUG) to $107 from $126 and keeps an Outperform rating on the shares. The firm updated its model following the placement…
Bright Minds Biosciences Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Bright Minds Biosciences (DRUG)
The FDA cited mouse toxicity findings and insufficient pharmacokinetic and juvenile-toxicity data when it placed Bright Minds' planned Phase 2 BMB-101 epilepsy trial on partial clinical hold. An inves...
Bright Minds price target lowered to $37 from $147 at BTIG
BTIG lowered the firm’s price target on Bright Minds (DRUG) to $37 from $147 and keeps a Buy rating on the shares after the company announced that the FDA has…
Why Did Bright Minds Biosciences Stock (DRUG) Plummet 55% Today?
Bright Minds Biosciences stock fell hard on Monday following an FDA update that put a partial clinical hold on one of its drug candidates.
Bright Minds BMB-101 partial hold clouds U.S. DEE timeline, says H.C. Wainwright
H.C. Wainwright notes Bright Minds (DRUG) Biosciences has announced an FDA partial clinical hold on the planned U.S. Phase 2 trial evaluating BMB-101, its selective serotonin 2C receptor agonist, in…
FDA places clinical hold on Bright Minds BMB-101-105 IND application
Bright Minds (DRUG) announced that the FDA has notified the company via email that its investigational new drug application, or IND, for Developmental and Epileptic Encephalopathies, or DEEs, and rela...
Bright Minds Biosciences Provides Update About Planned Study with BMB-101 in Developmental and Epileptic Encephalopathies
NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces that the U.S. Food and Drug Administration (“FDA”) has ...
Bright Minds initiated with an Outperform at Wolfe Research
Wolfe Research initiated coverage of Bright Minds (DRUG) with an Outperform rating and $150 price target
Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a clinical stage biotechnology company focused on developing hi...
Bright Minds initiated with an Outperform at LifeSci Capital
LifeSci Capital analyst Francois Brisebois initiated coverage of Bright Minds (DRUG) with an Outperform rating and $146 price target
Bright Minds Biosciences to Present at Upcoming Conferences
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 a...
Bright Minds Biosciences MD&A: Q3 2026
Bright Minds Biosciences filed a regulatory document on August 14, 2026 disclosing important business information.
Bright Minds Biosciences Report: Q3 2026
Bright Minds Biosciences published a report on August 14, 2026 containing material business information for investors and shareholders.
Vistagen Appoints Douglas J. Williamson to its Board of Directors
SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to dev...
Bright Minds Biosciences Transcript: Jefferies Global Healthcare Conference 2026
Lead 5-HT2C agonist BMB-101 showed robust efficacy and safety in phase II for absence seizures and DEE, with phase III trials starting later this year and data expected in 2024. Market potential is significant, and the asset offers key advantages over competitors in dosing, safety, and mechanism.
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 ago...
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline
Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model.
Bright Minds price target raised to $220 from $190 at Piper Sandler
Piper Sandler raised the firm’s price target on Bright Minds (DRUG) to $220 from $190 and keeps an Overweight rating on the shares. The firm caught up with Bright Minds…
Bright Minds Biosciences Report: Q2 2026
Bright Minds Biosciences published a report on May 19, 2026 containing material business information for investors and shareholders.
Bright Minds Biosciences MD&A: Q2 2026
Bright Minds Biosciences filed a regulatory document on May 19, 2026 disclosing important business information.
Bright Minds initiated with a Buy at Jefferies
Jefferies initiated coverage of Bright Minds (DRUG) with a Buy rating and $145 price target The firm says the company’s oral BMB-101 is a potential best-in-class 5-HT2C agonist. BMB-101 has
Bright Minds Biosciences Transcript: TD Cowen 46th Annual Health Care Conference
BMB-101 demonstrated strong efficacy and safety in refractory seizure disorders, with phase III trials in epilepsy and Prader-Willi syndrome underway. Both indications are seen as multi-billion dollar opportunities, and recent financing supports multiple upcoming clinical readouts.